drugset / Trial / NCT02428036
A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether TBI-1401(HF10), a spontaneously attenuated mutant of Herpes Simplex Virus Type 1 (HSV-1), is safe and tolerable in the treatment of solid tumors with superficial lesions.
Timeline
- Start
- 2015-06
- Primary completion
- 2016-10
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CANERPATUREV | Other / unclassified | 1e+06 unknown | Other |
| Subject | CANERPATUREV | Other / unclassified | 1e+07 unknown | Other |